ePrints

SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms

Lookup NU author(s): Dr Jose Luis Marin-RubioORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Abstract

© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.Despite the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway being frequently altered in T-ALL/LBL, no specific therapy has been approved for T-ALL/LBL patients with constitutive signalling by JAK/STAT, so there is an urgent need to identify pathway members that may be potential therapeutic targets. In the present study, we searched for JAK/STAT pathway members potentially modulated through aberrant methylation and identified SOCS3 hypermethylation as a recurrent event in T-ALL/LBL. Additionally, we explored the implications of SOCS3 deregulation in T-ALL/LBL and demonstrated that SOCS3 counteracts the constitutive activation of the JAK/STAT pathway through different molecular mechanisms. Therefore, SOCS3 emerges as a potential therapeutic target in T-ALL/LBL.

Publication metadata

Author(s): Lahera A, Lopez-Nieva P, Alarcon H, Marin-Rubio JL, Cobos-Fernandez MA, Fernandez-Navarro P, Fernandez AF, Vela-Martin L, Sastre I, Ruiz-Garcia S, Llamas P, Lopez-Lorenzo JL, Cornago J, Santos J, Fernandez-Piqueras J, Villa-Morales M

Publication type: Article

Publication status: Published

Journal: British Journal of Haematology

Year: 2023

Volume: 201

Issue: 4

Pages: 718-724

Print publication date: 01/05/2023

Online publication date: 14/02/2023

Acceptance date: 31/01/2023

Date deposited: 28/02/2023

ISSN (print): 0007-1048

ISSN (electronic): 1365-2141

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1111/bjh.18694

DOI: 10.1111/bjh.18694

PubMed id: 36786170

Altmetrics

Funding

Share